Although not planned for AML, many strategies have been shown to improve CAR T-cell expansion and persistence, including the expression of IL15 or IL18 and the addition of exogenous IL7, IL15, and IL21 during ex vivo CAR T-cell expansion [131,132,133,134]. This evidence concerns the gene IL15 and acute myeloid leukemia.